drugset / Trial / NCT00003046
Interleukin-12 in Treating Patients With Cancer in the Abdomen
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen.
Timeline
- Start
- 1997-08
- Primary completion
- 2001-10
- Completion
- 2001-10
Publications
- Results Lenzi R, Kudelka AP, Veschraegen C, et al.: Intraperitoneal (IP) bioimmunologic responses in patients with ovarian and gastrointestinal cancers at a low toxicity dosing schedule of IP recombinant interleukin-12 (rhIL-12). [Abstract] Proc Am Assoc Cancer Res 40: A3778, 573, 1999.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interleukin-12 | Protein / enzyme biologic | — | Other |